NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT00170573 2024-12-16
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02865811 2022-09-13
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT00913835 2019-09-26
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03804866 2019-01-15
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT01113957 2018-06-06
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
AbbVie
Phase 2 Completed
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT03335241 2017-11-13
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT00523380 2017-03-01
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Novo Nordisk A/S
Phase 2 Completed
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00945139 2015-07-31
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00312650 2015-01-12
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT00722592 2015-01-07
PRECEDENT
Endocyte
Phase 2 Completed
NCT01388621 2013-08-20
PROVE
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Unknown
NCT00003896 2013-01-04
S9912 Combination Chemo in Stage III Ovarian Cancer,
SWOG Cancer Research Network
Phase 2 Completed
NCT00861120 2012-10-26
PaLiDo
Vejle Hospital
Phase 2 Completed
NCT00653328 2012-05-23
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00610792 2009-07-14
Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
Millennium Pharmaceuticals, Inc.
Phase 2 Withdrawn